Daiichi Sankyo signs a $300m deal with Alteogen to develop a subcutaneous version of anti-HER2 cancer drug Enhertu.

A year ago, MSD and Daiichi Sankyo's HER3-targeting antibody-drug conjugate patritumab deruxtecan (HER3-DXd) was rejected by the FDA, and the partners have now withdrawn a filing intended to get ...

US FDA grants breakthrough therapy designation to Daiichi Sankyo & AstraZeneca’s Enhertu plus pertuzumab to treat unresectable or metastatic HER2 positive breast cancer Tokyo Friday, July 18, 2025, 14 ...

A high-level overview of Daiichi Sankyo Company, Limited (DSKYF) stock. View (DSKYF) real-time stock price, chart, news, analysis, analyst reviews and more.

View the latest Daiichi Sankyo Co. Ltd. (DSKYF) stock price, news, historical charts, analyst ratings and financial information from WSJ.

NHK has learned that work to remove molten fuel debris at the Fukushima Daiichi nuclear power plant is not likely to start until the late 2030s at the earliest.

The operator of a nuclear power plant in central Japan says it will resume onsite surveys toward constructing a next-generation reactor within the facility. If built, it would be the first new ...

Review quarterly and annual revenue, net income, and cash flow for Daiichi Kensetsu Corp (1799:XTKS) stock through the last fiscal year.

Comprehensive analysis of the NTM therapeutics market: Overview of disease, epidemiology, treatment options, and forecast from 2023-2033 for 7 major markets. Insights include pipeline trends ...

See the latest Daiichi Sankyo Co Ltd stock price (4568:XTKS), related news, valuation, dividends and more to help you make your investing decisions.